These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21701907)

  • 1. Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.
    Comabella M; Vandenbroeck K
    Curr Neurol Neurosci Rep; 2011 Oct; 11(5):484-91. PubMed ID: 21701907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.
    Grossman I; Knappertz V; Laifenfeld D; Ross C; Zeskind B; Kolitz S; Ladkani D; Hayardeny L; Loupe P; Laufer R; Hayden M
    Prog Neurobiol; 2017 May; 152():114-130. PubMed ID: 26952809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
    Mahurkar S; Suppiah V; O'Doherty C
    Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis].
    Tsareva EY; Favorova OO; Boyko AN; Kulakova OG
    Mol Biol (Mosk); 2019; 53(4):574-599. PubMed ID: 31397433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
    Tsareva E; Kulakova O; Boyko A; Favorova O
    Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics of interferon-β in multiple sclerosis: what has been accomplished and how can we ensure future progress?
    Carlson RJ; Doucette JR; Knox K; Nazarali AJ
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):249-61. PubMed ID: 25524087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of multiple sclerosis: in search for a personalized therapy.
    Martinez-Forero I; Pelaez A; Villoslada P
    Expert Opin Pharmacother; 2008 Dec; 9(17):3053-67. PubMed ID: 19006478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis: pharmacogenomics and personalised drug treatment.
    Annibali V; Ristori G; Cannoni S; Romano S; Visconti A; Ghazaryan A; Figà Talamanca L; Salvetti M; Mechelli R
    Neurol Sci; 2006 Sep; 27 Suppl 5():S347-9. PubMed ID: 16998717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis.
    Vandenbroeck K; Comabella M
    J Interferon Cytokine Res; 2010 Oct; 30(10):727-32. PubMed ID: 20836710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFN-beta pharmacogenomics in multiple sclerosis.
    Vandenbroeck K; Urcelay E; Comabella M
    Pharmacogenomics; 2010 Aug; 11(8):1137-48. PubMed ID: 20712530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
    Kulakova OG; Tsareva EY; Lvovs D; Favorov AV; Boyko AN; Favorova OO
    Pharmacogenomics; 2014 Apr; 15(5):679-85. PubMed ID: 24798724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
    Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
    Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C; Aloi JJ
    Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen.
    Vandenbroeck K; Matute C
    Pharmacogenomics; 2008 May; 9(5):639-45. PubMed ID: 18466107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach.
    Vosslamber S; van Baarsen LG; Verweij CL
    Pharmacogenomics; 2009 Jan; 10(1):97-108. PubMed ID: 19102719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rs205764 and rs547311 in linc00513 may influence treatment responses in multiple sclerosis patients: A pharmacogenomics Egyptian study.
    Amin NS; Abd El-Aziz MK; Hamed M; Moustafa RR; El Tayebi HM
    Front Immunol; 2023; 14():1087595. PubMed ID: 36883100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci.
    Kulakova O; Bashinskaya V; Kiselev I; Baulina N; Tsareva E; Nikolaev R; Kozin M; Shchur S; Favorov A; Boyko A; Favorova O
    Pharmacogenomics; 2017 Nov; 18(17):1563-1574. PubMed ID: 29095108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management.
    Stuart WH
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S19-25. PubMed ID: 15253686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.